Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Decoy Therapeutics (DCOY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($1.2 million vs $995,881), about 1.2 times the size. On valuation, Biodexa Pharmaceuticals American Depositary Shs trades at a lower trailing P/E (0.0x vs 0.1x for Decoy Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | DCOY |
|---|---|---|
| Share price | $0.5237 | $1.52 |
| Market cap | $1.15M | $995.88K |
| 1-day change | -7.11% | -5.59% |
| P/E ratio (TTM) | 0.01 | 0.12 |
| EPS (TTM) | $63.74 | $12.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $55.92 |
| 52-week low | $0.511 | $1.48 |
| Distance from 52-week high | -98.99% | -97.28% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1601.36% | +97.37% |
| Average volume | 3.72M | 2.17M |
| Shares outstanding | 2.20M | 655.18K |
| Employees | 11 | 11 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Decoy Therapeutics trades at a higher earnings multiple (0.1x vs 0.0x trailing P/E).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Healthcare · Biotechnology · 11 employees
About Decoy Therapeutics
DCOY stock →Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
Healthcare · Biotechnology · 11 employees
BDRX vs DCOY FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Decoy Therapeutics?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $1.15M compared with $995.88K for Decoy Therapeutics (DCOY).
Which has the lower P/E ratio, BDRX or DCOY?
BDRX has the lower trailing P/E at 0.0, versus 0.1 for DCOY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biodexa Pharmaceuticals American Depositary Shs and Decoy Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.